Fierce Pharma
Fierce Biotech
Fierce Healthcare
Fierce Life Sciences Events
Advertise
About Us
Pharma
Vaccines
Asia
Cell & Gene Therapy
Drug Delivery
Executives
Manufacturing
Facilities
Recalls
Warning Letters
Marketing
Special Reports
Fierce 50
Special Report
Awards Gala
Trending
Oncology
Supply Chain
Awards
CRO Awards
Innovation Awards
Pharma Marketing Awards
Resources
Podcasts
Fierce Events
Industry Events
Webinars
Whitepapers
Survey
Events
Subscribe
Subscribe
Pharma
Vaccines
Asia
Cell & Gene Therapy
Drug Delivery
Executives
Manufacturing
Facilities
Recalls
Warning Letters
Marketing
Special Reports
Fierce 50
Special Report
Awards Gala
Trending
Oncology
Supply Chain
Awards
CRO Awards
Innovation Awards
Pharma Marketing Awards
Resources
Podcasts
Fierce Events
Industry Events
Webinars
Whitepapers
Survey
Events
Subscribe
Fierce Pharma
Fierce Biotech
Fierce Healthcare
Fierce Life Sciences Events
Advertise
About Us
targeted therapies
Pharma
Pfizer scores again in HER2-positive breast cancer
The positive readout could move Tukysa, which has been used for second-line, HER2-positive breast cancer, into the first-line maintenance setting.
Angus Liuu
Oct 14, 2025 12:33pm
In a first, FDA approves Servier's Voranigo in low-grade gliomas
Aug 6, 2024 5:25pm
FDA clears Bristol Myers cancer drug from Turning Point buy
Nov 16, 2023 11:10am
ESMO: Roche's Alecensa cuts postsurgery lung cancer recurrence
Oct 21, 2023 10:30am
Roche pulls a Gavreto cancer indication, citing unfeasible trial
Jul 5, 2023 12:16pm
Lilly, Merck bet billions in biobucks on peptide-based delivery
Jan 3, 2023 8:40am
